FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220951582> ?p ?o ?g. }

• W4220951582 endingPage "238" @default.
• W4220951582 startingPage "230" @default.
• W4220951582 abstract "Abstract Diffuse large B cell lymphoma (DLBCL) is the most common aggressive lymphoid malignancy, with an immunosuppressive microenvironment affecting clinical outcome. Interleukin (IL)‐13 overexpression is observed in multiple solid tumors and contributes to tumor progression. This study aims to investigate pretreatment serum IL‐13 levels and their relationship with the prognosis of DLBCL patients. One hundred and sixty‐six patients with newly diagnosed DLBCL from June 2015 to July 2017 were included. Patients with elevated pretreatment serum IL‐13 levels (IL‐13≥1.63 pg/ml) were classified into the high IL‐13 group and they had significantly lower complete remission rate (60% vs. 74%, p = 0.0059), higher progression rate (43% vs. 23%, p = 0.0051), and poor progression‐free survival (2‐year PFS, 63% vs. 78%, p = 0.0078) and overall survival (2‐year OS, 75% vs. 92%, p = 0.0027), when compared to those in the low IL‐13 group (IL‐13<1.63 pg/ml). Meanwhile, increased Treg cell ratio in peripheral blood ( p = 0.0147) and elevated serum IL‐2 levels ( p = 0.0272) were observed in the high IL‐13 group. Moreover, RNA sequencing data showed that patients in the high IL‐13 group had significantly elevated expression of chemokines and chemokine receptors (CCR4, CCL19, CCL21, CXCL2) related to Treg activation and recruitment. Consistent with the chemokine profile, tumor immunophenotyping analysis revealed that higher Treg cells recruitment in the high IL‐13 group than the low IL‐13 group ( p = 0.0116). In vitro, when lymphoma cells co‐cultured with peripheral blood monocytes of healthy controls, metformin down‐regulated both IL‐13 level and Treg cell ratio, in consistent with the decreased serum IL‐13 levels of patients after 6 months of metformin maintenance therapy in the high IL‐13 group. Taken together, pretreatment serum IL‐13 level is related to the immunosuppressive microenvironment and poor clinical outcome of DLBCL patients and could be targeted by metformin, thus providing a new therapeutic strategy in treating DLBCL with high serum IL‐13 levels." @default.
• W4220951582 created "2022-04-03" @default.
• W4220951582 creator A5001946970 @default.
• W4220951582 creator A5005437138 @default.
• W4220951582 creator A5009929030 @default.
• W4220951582 creator A5012278873 @default.
• W4220951582 creator A5030734272 @default.
• W4220951582 creator A5057644948 @default.
• W4220951582 creator A5069739901 @default.
• W4220951582 creator A5086006017 @default.
• W4220951582 creator A5090495842 @default.
• W4220951582 date "2022-04-04" @default.
• W4220951582 modified "2023-10-16" @default.
• W4220951582 title "Elevated serum IL‐13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B‐cell lymphoma" @default.
• W4220951582 cites W1912693401 @default.
• W4220951582 cites W1980742715 @default.
• W4220951582 cites W2020789296 @default.
• W4220951582 cites W2023064301 @default.
• W4220951582 cites W2147856602 @default.
• W4220951582 cites W2320278018 @default.
• W4220951582 cites W2344619913 @default.
• W4220951582 cites W2519625564 @default.
• W4220951582 cites W2561926137 @default.
• W4220951582 cites W2565788901 @default.
• W4220951582 cites W2585139079 @default.
• W4220951582 cites W2742254242 @default.
• W4220951582 cites W2756237427 @default.
• W4220951582 cites W2765136070 @default.
• W4220951582 cites W2767159687 @default.
• W4220951582 cites W2793344857 @default.
• W4220951582 cites W2806376977 @default.
• W4220951582 cites W2883081969 @default.
• W4220951582 cites W2884693661 @default.
• W4220951582 cites W2887888154 @default.
• W4220951582 cites W2894075720 @default.
• W4220951582 cites W2894606588 @default.
• W4220951582 cites W2903708727 @default.
• W4220951582 cites W2906738980 @default.
• W4220951582 cites W2938758635 @default.
• W4220951582 cites W2946663348 @default.
• W4220951582 cites W2971660841 @default.
• W4220951582 cites W2983326574 @default.
• W4220951582 cites W2994925202 @default.
• W4220951582 cites W3000715731 @default.
• W4220951582 cites W3021809450 @default.
• W4220951582 cites W3082016908 @default.
• W4220951582 cites W3091042718 @default.
• W4220951582 cites W3096895222 @default.
• W4220951582 cites W3110295488 @default.
• W4220951582 cites W4234118229 @default.
• W4220951582 cites W560907111 @default.
• W4220951582 doi "https://doi.org/10.1002/hon.2993" @default.
• W4220951582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35304777" @default.
• W4220951582 hasPublicationYear "2022" @default.
• W4220951582 type Work @default.
• W4220951582 citedByCount "4" @default.
• W4220951582 countsByYear W42209515822022 @default.
• W4220951582 countsByYear W42209515822023 @default.
• W4220951582 crossrefType "journal-article" @default.
• W4220951582 hasAuthorship W4220951582A5001946970 @default.
• W4220951582 hasAuthorship W4220951582A5005437138 @default.
• W4220951582 hasAuthorship W4220951582A5009929030 @default.
• W4220951582 hasAuthorship W4220951582A5012278873 @default.
• W4220951582 hasAuthorship W4220951582A5030734272 @default.
• W4220951582 hasAuthorship W4220951582A5057644948 @default.
• W4220951582 hasAuthorship W4220951582A5069739901 @default.
• W4220951582 hasAuthorship W4220951582A5086006017 @default.
• W4220951582 hasAuthorship W4220951582A5090495842 @default.
• W4220951582 hasConcept C121608353 @default.
• W4220951582 hasConcept C126322002 @default.
• W4220951582 hasConcept C13373296 @default.
• W4220951582 hasConcept C170493617 @default.
• W4220951582 hasConcept C203014093 @default.
• W4220951582 hasConcept C2776107976 @default.
• W4220951582 hasConcept C2778559949 @default.
• W4220951582 hasConcept C2779256057 @default.
• W4220951582 hasConcept C2779338263 @default.
• W4220951582 hasConcept C2779727006 @default.
• W4220951582 hasConcept C71924100 @default.
• W4220951582 hasConcept C8891405 @default.
• W4220951582 hasConcept C90924648 @default.
• W4220951582 hasConceptScore W4220951582C121608353 @default.
• W4220951582 hasConceptScore W4220951582C126322002 @default.
• W4220951582 hasConceptScore W4220951582C13373296 @default.
• W4220951582 hasConceptScore W4220951582C170493617 @default.
• W4220951582 hasConceptScore W4220951582C203014093 @default.
• W4220951582 hasConceptScore W4220951582C2776107976 @default.
• W4220951582 hasConceptScore W4220951582C2778559949 @default.
• W4220951582 hasConceptScore W4220951582C2779256057 @default.
• W4220951582 hasConceptScore W4220951582C2779338263 @default.
• W4220951582 hasConceptScore W4220951582C2779727006 @default.
• W4220951582 hasConceptScore W4220951582C71924100 @default.
• W4220951582 hasConceptScore W4220951582C8891405 @default.
• W4220951582 hasConceptScore W4220951582C90924648 @default.
• W4220951582 hasFunder F4320321001 @default.
• W4220951582 hasIssue "2" @default.
• W4220951582 hasLocation W42209515821 @default.
• W4220951582 hasLocation W42209515822 @default.

• next